Intensified Radiotherapy for Prostate Cancer Bone Metastases

A regional retrospective study covering 2011 to 2025 suggests that a more intensive radiotherapy strategy may improve survival in selected patients with prostate cancer and bone metastases. The analysis included 246 consecutive men who received 347 radiotherapy courses and asked whether treating bone lesions more aggressively, together with prostate-directed radiotherapy, could translate into longer overall survival.

The study found that survival was poorest in the earliest period, while the two more recent cohorts had similar and better outcomes.The best results were seen in outpatients with good performance status, treatment delivered early after diagnosis, and radiotherapy aimed at all known sites of disease, a pattern that fits the broader move from purely palliative radiation toward metastasis-directed treatment in carefully selected patients.

In the subgroup without visceral metastases treated within the first year after diagnosis, prostate radiotherapy was associated with a numerical survival advantage, with median overall survival of 40 months versus 26 months and 5-year survival of 47% versus 18%, although the p value of 0.11 means the result was not statistically significant. Even so, the direction of effect is consistent with the wider literature supporting local treatment of the primary tumor in low-burden metastatic disease.

The most compelling finding involved dose to bone metastases. Higher-dose bone radiotherapy was associated with significantly better 5-year survival in both synchronous and metachronous disease, and this association remained significant in multivariable analyses together with baseline clinical factors. That does not remove the possibility of selection bias, but it strengthens the argument that dose intensity may matter when radiotherapy is used with a consolidative rather than purely symptomatic intent.

Source.